Literature DB >> 21659541

Association of natural anti-platelet factor 4/heparin antibodies with periodontal disease.

Andreas Greinacher1, Birte Holtfreter, Krystin Krauel, Daniela Gätke, Claudia Weber, Till Ittermann, Sven Hammerschmidt, Thomas Kocher.   

Abstract

Platelet factor 4 (PF4) and heparin (H) form PF4/H complexes, the target of the immune reaction in heparin-induced thrombocytopenia (HIT). HIT seems to be a secondary immune response as anti-PF4/H-IgG antibodies occur as early as day 4 of heparin treatment. This study investigated whether prevalent infections such as periodontitis may induce the PF4/H immune response as: (1) natural anti-PF4/H Abs are present in the normal population; (2) PF4 bound to bacteria exposes the same antigen(s) as PF4/H complexes; and (3) sepsis induces PF4/H Abs in mice. We found PF4 bound to periodontal pathogens (Aggregatibacter actinomycetemcomitans; Porphyromonas gingivalis) enabling subsequent binding of human anti-PF4/H Abs. The association of natural PF4/H Abs and periodontitis was assessed in a case-control study, enrolling individuals with natural anti-PF4/H Abs (n = 40 matched pairs), and in the cross-sectional population-based Study of Health in Pomerania (SHIP; n = 3500). Both studies showed a robust association between periodontitis and presence of anti-PF4/H Abs independent of inflammation markers (case-control study: lowest vs highest tertile, odds ratio, 7.12 [95% confidence interval, 1.73-46.13; P = .005]; SHIP study, p(trend) ≤ 0.001). Thus, preimmunization to PF4/bacteria complexes by prevalent infections, for example, periodontitis, likely explains the presence of natural anti-PF4/heparin Abs and the early occurrence of anti-PF4/H-IgG in HIT.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21659541     DOI: 10.1182/blood-2011-03-342857

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  29 in total

1.  Pharmacogenetics to prevent heparin-induced thrombocytopenia: what do we know?

Authors:  Jason H Karnes
Journal:  Pharmacogenomics       Date:  2018-11-06       Impact factor: 2.533

Review 2.  Drug-associated thrombocytopenia.

Authors:  Tamam Bakchoul; Irene Marini
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2018-11-30

Review 3.  Heparin-induced thrombocytopenia.

Authors:  Grace M Lee; Gowthami M Arepally
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2013

4.  Heparin enhances uptake of platelet factor 4/heparin complexes by monocytes and macrophages.

Authors:  M Joglekar; S Khandelwal; D B Cines; M Poncz; L Rauova; G M Arepally
Journal:  J Thromb Haemost       Date:  2015-07-14       Impact factor: 5.824

Review 5.  Heparin-induced thrombocytopenia: research and clinical updates.

Authors:  Oluwatoyosi Onwuemene; Gowthami M Arepally
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2016-12-02

Review 6.  Immune pathogenesis of heparin-induced thrombocytopenia.

Authors:  Sanjay Khandelwal; Gowthami M Arepally
Journal:  Thromb Haemost       Date:  2016-07-28       Impact factor: 5.249

Review 7.  Advances in the pathophysiology and treatment of heparin-induced thrombocytopenia.

Authors:  Steven E McKenzie; Bruce S Sachais
Journal:  Curr Opin Hematol       Date:  2014-09       Impact factor: 3.284

Review 8.  Heparin induced thrombocytopenia in critically ill: Diagnostic dilemmas and management conundrums.

Authors:  Sachin Gupta; Ravindranath Tiruvoipati; Cameron Green; John Botha; Huy Tran
Journal:  World J Crit Care Med       Date:  2015-08-04

Review 9.  Molecular and cellular pathogenesis of heparin-induced thrombocytopenia (HIT).

Authors:  Lubica Rauova; Gowthami Arepally; Mortimer Poncz; Douglas B Cines
Journal:  Autoimmun Rev       Date:  2018-08-10       Impact factor: 9.754

10.  Relationship between the 4Ts scoring system and the antiplatelet factor 4/heparin antibodies test in critically ill patients.

Authors:  Yosuke Matsumura; Taka-Aki Nakada; Shigeto Oda
Journal:  Acute Med Surg       Date:  2013-12-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.